This market research report includes a detailed segmentation of the global choroidal neovascularization market by route of administration (IV and Intravitreal) and by geography (Americas, EMEA and APAC). The top vendors analyzed in this report are Bayer, F. Hoffmann-La Roche, Novartis, and Regeneron Pharmaceuticals.
Technavio’s market research analysts estimate the global choroidal neovascularization market, to grow at a CAGR of 6% between 2016 and 2020. Choroidal neovascularization is a condition affecting older people, who are at a higher risk of losing their central field of vision. Rise in treatment rates and a high annual cost of therapy for the market-approved drugs are boosting the growth of choroidal neovascularization market. The Americas is the largest revenue-contributing market, owing to the promising choroidal neovascularization pipeline.
The new market research report from Technavio provides a breakdown and analysis of the choroidal neovascularization segments by technology.
“The choroidal neovascularization drugs market is witnessing shift toward combination therapies, which uses two or more effective treatments. The combination therapy will block the multiple stimuli that lead to pathologic cellular proliferation. The currently marketed combination products include PDT with Visudyne and anti-VEGF therapies (Lucentis, Avastin, and Macugen), which have been evaluated primarily in patients with choroidal neovascularization due to AMD,” says IOmran Mushtaq, Industry Manager, Healthcare & Lifesciences, Technavio Research
Intravitreal (or inside-the-eye) drug administration is the preferred route of administration (ROA), occupying 87% of the total market share. This method maximizes the therapeutic intraocular concentration and reduces the risk of the drug being spread to other sites in the body. Despite the risks, the intravitreal route is popular because of the increased use of VEGF inhibitors (EYLEA and Lucentis), which are primarily administered through this route.
The key vendors in global choroidal neovascularization market are Bayer, F. Hoffmann-La Roche, Novartis, and Regeneron Pharmaceuticals. The market is growing at a moderate pace because of the increased demand for choroidal neovascularization therapeutics. The market is highly competitive because of the presence of numerous small and large vendors. The emerging players are expected to bring a considerable shift in the market positioning of the existing market leaders.
A more detailed analysis is available in the Technavio report, Global Choroidal Neovascularization Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
